Recent Updates
Recently added Catalysts

Urothelial Cancer: 4 biotech companies with clinical-stage programmes

OncologyConcentrated betData as of 2026-11-15

Competitors4in the clinic
Median market cap$1.2Buniverse median $1.03B
Allocated capital$2.7B$19.4B competing
Phase 3 or filed00 mid, 4 early
Pure plays0this indication only
Capital rank71/299crowding rank 42

Urothelial Cancer is a concentrated bet: only 4 US-listed developers are in the clinic, and the median one is worth $1.2B against a $1.03B universe median.

Scarcity is doing the work in that number. A thin field means an approval is shared with fewer rivals, and the market pays a premium for that position.

EXEL alone accounts for 87% of the $19.4B of market capitalisation competing here, so this is a leader plus a tail rather than a level race.

$2.7B of allocated capital sits in Urothelial Cancer, ranking it 71st of 299 indications by the money committed to it.

Companies developing drugs for Urothelial Cancer 4

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
EXELExelixisCabozantinibPhase 11$16.8BNo10 3 Mar 2027
GENBGenerate BiomedicinesGB-4362Phase 11$1.5BNo3No dated event
AKTSAktis OncologyAc-AKY-1189Phase 12$924MNo2No dated event
MGNXMacroGenicsMGC030Phase 11$140MNo2 30 Jun 2027

Sorted by phase, then by market capitalisation. Ticker links open the company profile. EXEL holds 87% of the $19.4B competing in this indication.

Why Urothelial Cancer is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.03B counts as richly priced. Urothelial Cancer has 4 competitors and a median of $1.2B.

Oncology

Oncology holds $154B of the map's capital, 26.9% of the total, spread across 93 indications and 93 companies. 38 of those indications have more than one company competing.

See every Oncology indication on the map

Urothelial Cancer pipeline questions

Which biotech companies are developing drugs for Urothelial Cancer?

Exelixis (EXEL, Cabozantinib, Phase 1); Generate Biomedicines (GENB, GB-4362, Phase 1); Aktis Oncology (AKTS, Ac-AKY-1189, Phase 1); MacroGenics (MGNX, MGC030, Phase 1). Those are the 4 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Urothelial Cancer.

How advanced is the Urothelial Cancer pipeline?

Of the 4 clinical-stage programmes in Urothelial Cancer, 0 are in Phase 3 or filed, 0 are in mid-stage development and 4 are in early-stage development.

Which company leads the Urothelial Cancer field?

EXEL is the largest developer in Urothelial Cancer, holding 87% of the $19.4B of market capitalisation competing in the indication. The median competitor is worth $1.2B.

When is the next Urothelial Cancer catalyst?

The next dated catalyst in Urothelial Cancer is EXEL on 3 Mar 2027. 2 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map